dcsimg Aranesp® (darbepoetin alfa) – Efficacy for Patients Not on Dialysis
› Email› Print

Aranesp® demonstrated consistent efficacy in patients with anemia
due to CKD not on dialysis

Aranesp® demonstrated consistent efficacy in patients with anemia due to CKD not on dialysis

For patients with CKD not on dialysis, Aranesp® is administered Q4W
intravenously or subcutaneously as appropriate

For patients with CKD not on dialysis, Aranesp® is administered Q4W intravenously or subcutaneously as appropriate
  • Consider initiating Aranesp® treatment only when Hb level is < 10 g/dL and the following
    considerations apply:
    • The rate of Hb decline indicates the likelihood of requiring a RBC transfusion and,
    • Reducing the risk of alloimmunization and/or other RBC transfusion-related risks is a goal.
  • If the Hb level exceeds 10 g/dL, reduce or interrupt the dose of Aranesp®, and use the lowest dose of Aranesp® sufficient to reduce the need for RBC transfusions.
  • Q4W recommended starting dose: 0.45 mcg/kg body weight as an IV or SC injection once at 4-week intervals as appropriate.

Important Safety Information

Aranesp® is contraindicated in patients with:

  • Uncontrolled hypertension
    • Pure red cell aplasia (PRCA) that begins after treatment with Aranesp® or other erythropoietin protein drugs
    • Serious allergic reactions to Aranesp®

Scroll down for additional
Important Safety Information.

Abbreviations and References:
CKD = chronic kidney disease; ESA = erythropoiesis-stimulating agent; Hb = hemoglobin; IV = intravenous; mITT = modified intent-to-treat patients enrolled in the study and received at least 1 dose of study drug; QW = once weekly; Q2W = once every 2 weeks; Q4W = once every 4 weeks; RBC = red blood cell; SC = subcutaneous; TIW = three times weekly.
References: 1. Locatelli F, Olivares J, Walker R, et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int. 2001;60:741-747. 2. Suranyi MG, Lindberg JS, Navarro J, et al. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol. 2003;23:106-111. 3. Silver MR, Geronemus R, Krause M, et al. Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naive to erythropoiesis stimulating agents. Curr Med Res Opin. 2009;25:123-131.

Biotechnology by Amgen®